Kayflo-OZ Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Ornidazole 500 mg, designed for the treatment of mixed bacterial and protozoal infections. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against both Gram-positive and Gram-negative organisms. Ornidazole, a nitroimidazole derivative, possesses potent antiprotozoal and antibacterial properties, primarily targeting anaerobic bacteria and protozoa by disrupting DNA synthesis and causing cell death. This synergistic combination is indicated for infections such as urinary tract infections, respiratory tract infections, gastrointestinal infections including amoebiasis, and mixed anaerobic infections. Kayflo-OZ is particularly useful in cases where polymicrobial infections are suspected or confirmed. The tablet should be administered orally as prescribed by a healthcare professional, with dosage adjusted based on the severity of infection and patient response. Caution is advised in patients with hypersensitivity to cephalosporins or nitroimidazoles, and use is contraindicated during the first trimester of pregnancy. Common adverse effects may include gastrointestinal disturbances, headache, and hypersensitivity reactions. Kayflo-OZ Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and minimize resistance development.